LivingGLP1
Study S000347

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

Registration

Registration
NCT06914102
Acronym
DUP-STEP-HFpEF
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
58387
Start
2025-01-14
Primary completion
2025-06-01
Lead sponsor
Brigham and Women's Hospital
Conditions
Diabetes Mellitus, Type 2; HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
DRUG:Semaglutide; DRUG:Placebo
Results posted
FALSE

Registered primary outcomes

  • Composite of all-cause mortality or heart failure hospitalization [Through study completion (1 day after cohort entry date until the first of outcome or censoring)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0009707Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
Krüger N, JAMA
2025Nonrandomized studyPMID 40886075DOIcites ClinicalTrials.gov:NCT06914102; registry reference DERIVED:40886075